Given the frequently reported inadequacies of conventional cancer therapies and the growing need for personalized medicines, there is a surge in demand for TIL-based therapies. Considering the encouraging clinical trial data and the rising need for safe and efficacious therapies, TIL-based therapies have generated significant enthusiasm among medical R&D professionals in cancer centers around the world. Based on multiple clinical and preclinical stage success stories, TIL-based therapies are anticipated to carve out a significant share of the multi-billion-dollar cancer immunotherapy market.